ScripWith biopharma investors eager for hard numbers on the impact of the Trump administration’s tariff policy on corporate financials, Merck & Co. CEO Robert Davis offered some answers on 24 April, sa
ScripMultiple major Chinese vaccine manufacturers are expecting annual profits to have slumped in 2024, as fiercer competition, destocking at vaccination clinics and a slowing Chinese economy all weigh on
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of
ScripWho: UCB/CBC Group/Mubadala What: UCB is divesting some mature neurology and allergy products in China, as well as a manufacturing site in that country, to CBC and Mubadala. Why: UCB said the tra